9 research outputs found

    Number of co-medications used and percentage of patients, by DAA regimen, among HCV-infected patients.

    No full text
    <p>(A) Patients with mild liver disease. (B) Patients with moderate-to severe-liver disease. SOF/RBV: sofosbuvir plus ribavirin, SOF/SIM: sofosbuvir plus simeprevir, SOF/DCV: sofosbuvir plus daclatasvir, SOF/LDV: sofosbuvir plus ledipasvir, 3D: paritaprevir/ritonavir, ombitasvir, dasabuvir. The percentage of patients who took one drug (in blu), two drugs (in red), three drugs (in green) and more than 3 drugs (in violet) are reported considering the total number of patients reported for each regimen in both Fig 1A and Fig 1B at the same manner.</p

    Category of potential DDIs, by DAA regimen and severity of liver disease, among HCV-infected patients.

    No full text
    <p>Comedication used in patients with mild liver disease (A) or in (B) patients with moderate-to severe-liver disease (B). DAA regiments and number of comedications used are shown. SOF/RBV: sofosbuvir plus ribavirin, SOF/SIM: sofosbuvir plus simeprevir, SOF/DCV: sofosbuvir plus daclatasvir, SOF/LDV: sofosbuvir plus ledipasvir, 3D: paritaprevir/ritonavir, ombitasvir, dasabuvir. Category 0: Classification not possible due to lack of information; Category 1: No clinical interaction possible; Category 2: May require dose adjustment/closer monitoring.</p

    Univariate and logistic regression analysis linking failure with independent variables.

    No full text
    <p>Univariate and logistic regression analysis linking failure with independent variables.</p

    Failure rates following the first DAA regimen, by HCV genotype and treatment regimen in patients who completed the 12 weeks post treatment evaluation (n = 3,830 patients).

    No full text
    <p>Failure rates following the first DAA regimen, by HCV genotype and treatment regimen in patients who completed the 12 weeks post treatment evaluation (n = 3,830 patients).</p

    Modifications of liver disease stage following DAA treatment in patients with cirrhosis.

    No full text
    <p>(A) Baseline, post-failure and post-retreatment SVR12 changes of Child Pugh Class; (B) baseline and post-failure changes of Child Pugh Class for patients who were not retreated yet; (C) baseline and post-SVR12 changes of Child Pugh Class for patients who achieved SVR12 following the first DAA treatment. Bold arrows indicate patients who did not change the Child Pugh Class. Dashed arrows indicate patients who worsened the Child Pugh Class, whereas the grey arrows indicate patients who improved the Child Pugh class. In the curly brackets are reported the number of patients for specific changes observed in the Child Pugh classes in the three points of evaluation. n = number of patients.</p

    Characteristics of the study patients according to SVR following the first DAA treatment.

    No full text
    <p>Characteristics of the study patients according to SVR following the first DAA treatment.</p
    corecore